| . | GH-Treated Young PWS Children . | GH-Treated Older PWS Children . | P Value . |
|---|---|---|---|
| Male/Female | 12/8 | 10/10 | .530 |
| Genotype | .890 | ||
| Deletion | 11 | 11 | |
| mUPD | 8 | 7 | |
| ICD | 1 | 2 | |
| Age at start of GH treatment, y | 1.35 (0.97–1.70) | 6.05 (3.65–7.73) | <.001 |
| Blood sampling | |||
| Age, y | 5.2 (4.3–7.2) | 14.9 (13.8–16.2) | <.001 |
| Duration of GH treatment, y | 4.00 (2.95–5.70) | 9.04 (8.14–10.77) | <.001 |
| Dose GH, mg/m2 · d | 0.67 (0.50–1.00) | 1.00 (1.00–1.00) | .002 |
| Height SDS | −0.07 (−0.61 to 0.63) | −0.32 (−1.48 to 0.16) | .194 |
| BMI SDS | 0.89 (0.25–1.85) | 1.24 (0.23–1.66) | .646 |
| . | GH-Treated Young PWS Children . | GH-Treated Older PWS Children . | P Value . |
|---|---|---|---|
| Male/Female | 12/8 | 10/10 | .530 |
| Genotype | .890 | ||
| Deletion | 11 | 11 | |
| mUPD | 8 | 7 | |
| ICD | 1 | 2 | |
| Age at start of GH treatment, y | 1.35 (0.97–1.70) | 6.05 (3.65–7.73) | <.001 |
| Blood sampling | |||
| Age, y | 5.2 (4.3–7.2) | 14.9 (13.8–16.2) | <.001 |
| Duration of GH treatment, y | 4.00 (2.95–5.70) | 9.04 (8.14–10.77) | <.001 |
| Dose GH, mg/m2 · d | 0.67 (0.50–1.00) | 1.00 (1.00–1.00) | .002 |
| Height SDS | −0.07 (−0.61 to 0.63) | −0.32 (−1.48 to 0.16) | .194 |
| BMI SDS | 0.89 (0.25–1.85) | 1.24 (0.23–1.66) | .646 |
Data are expressed as median (IQR) or number (percentage). SDS was determined according to gestational age- and sex-matched reference values (21, 22). Bold indicates significant value. Abbreviations: mUPD, maternal uniparental disomy; ICD, imprinting center defect.
| . | GH-Treated Young PWS Children . | GH-Treated Older PWS Children . | P Value . |
|---|---|---|---|
| Male/Female | 12/8 | 10/10 | .530 |
| Genotype | .890 | ||
| Deletion | 11 | 11 | |
| mUPD | 8 | 7 | |
| ICD | 1 | 2 | |
| Age at start of GH treatment, y | 1.35 (0.97–1.70) | 6.05 (3.65–7.73) | <.001 |
| Blood sampling | |||
| Age, y | 5.2 (4.3–7.2) | 14.9 (13.8–16.2) | <.001 |
| Duration of GH treatment, y | 4.00 (2.95–5.70) | 9.04 (8.14–10.77) | <.001 |
| Dose GH, mg/m2 · d | 0.67 (0.50–1.00) | 1.00 (1.00–1.00) | .002 |
| Height SDS | −0.07 (−0.61 to 0.63) | −0.32 (−1.48 to 0.16) | .194 |
| BMI SDS | 0.89 (0.25–1.85) | 1.24 (0.23–1.66) | .646 |
| . | GH-Treated Young PWS Children . | GH-Treated Older PWS Children . | P Value . |
|---|---|---|---|
| Male/Female | 12/8 | 10/10 | .530 |
| Genotype | .890 | ||
| Deletion | 11 | 11 | |
| mUPD | 8 | 7 | |
| ICD | 1 | 2 | |
| Age at start of GH treatment, y | 1.35 (0.97–1.70) | 6.05 (3.65–7.73) | <.001 |
| Blood sampling | |||
| Age, y | 5.2 (4.3–7.2) | 14.9 (13.8–16.2) | <.001 |
| Duration of GH treatment, y | 4.00 (2.95–5.70) | 9.04 (8.14–10.77) | <.001 |
| Dose GH, mg/m2 · d | 0.67 (0.50–1.00) | 1.00 (1.00–1.00) | .002 |
| Height SDS | −0.07 (−0.61 to 0.63) | −0.32 (−1.48 to 0.16) | .194 |
| BMI SDS | 0.89 (0.25–1.85) | 1.24 (0.23–1.66) | .646 |
Data are expressed as median (IQR) or number (percentage). SDS was determined according to gestational age- and sex-matched reference values (21, 22). Bold indicates significant value. Abbreviations: mUPD, maternal uniparental disomy; ICD, imprinting center defect.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
